DexCom, Inc. $DXCM Stock Holdings Lifted by Nissay Asset Management Corp Japan

Nissay Asset Management Corp Japan increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.4% during the second quarter, Holdings Channel reports. The fund owned 115,276 shares of the medical device company’s stock after acquiring an additional 6,976 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in DexCom were worth $7,764,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Reflection Asset Management acquired a new position in DexCom in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in DexCom during the 1st quarter valued at $25,000. MCF Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter valued at $32,000. Wellington Grp LLC lifted its holdings in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares in the last quarter. Finally, DV Equities LLC acquired a new stake in shares of DexCom in the fourth quarter worth $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $90.82 on Monday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The stock has a market cap of $34.27 billion, a P/E ratio of 35.90, a P/E/G ratio of 1.53 and a beta of 1.41. The company’s fifty day simple moving average is $79.21 and its 200-day simple moving average is $71.61.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period last year, the company earned $0.48 earnings per share. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. TD Cowen reissued a “buy” rating on shares of DexCom in a research note on Friday, July 31st. JPMorgan Chase & Co. raised their price objective on DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Truist Financial set a $93.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, William Blair upgraded DexCom to a “strong-buy” rating in a report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Buying and Selling

In related news, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the sale, the insider owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president owned 100,361 shares in the company, valued at $7,326,353. This represents a 4.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 75,600 shares of company stock worth $5,673,342. Insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.